

	Room 1 (Grand Ballroom 3, 3F)	Room 2 (Grand Ballroom 2, 3F)	Room 3 (Grand Ballroom 1, 3F)	Room 4 (Park Ballroom 3, 5F)	Room 5 (Studio 2,3, 6F)
[Day 1] September 10(Thu), 2026					
12:00-	Registration				
13:00-14:30	Symposium 1 Nutritional Immunometabolism in Atherosclerosis	Symposium 2 (K) From Biobank to Biology: Integrative Platforms for Cardiometabolic Discovery	Symposium 3 Inflammation in ASCVD: From LDL Lowering to Immune Modulation	Symposium 4 *Session Time: 13:00-14:00 Publication Committee Session: JIA Award for Outstanding Article	
14:30-16:00	Oral Presentation 1	Symposium 5 FH/Severe Dyslipidemia: Optimizing FH Management	IHA-KSoLA Joint Symposium Optimizing Lipid-Lowering Strategies: Facing Challenges in Asian High-Risk Patients	Symposium 6 Neurocardiometabolic Benefits of GLP1 RA and SGLT2 Inhibitors	
16:00-16:10	Break				
16:10-17:40	Symposium 7 Real-world LDL-C Management: From Guideline to Prescription	JAS-KSoLA Joint Symposium Comprehensive Lipid Management in East Asians: Integrating LDL-C Optimization, Residual Risk, and Genetic Factors	Symposium 8 Metabolic Regulation of Lipid Metabolism: From Mechanisms to Cardiovascular Outcomes	Symposium 9 KSN KSoLA Joint Symposium Chronic Kidney Disease and Atherosclerosis	
17:40-	Welcome Reception (Lobby, Studio 4-7, 6F)				
[Day 2] September 11(Fri), 2026					
07:30-08:30	Breakfast Symposium 1 (K+E)	Breakfast Symposium 2	Breakfast Symposium 3	Breakfast Symposium 4	
08:30-10:00	Oral Presentation 2	Symposium 10 New Frontiers in Lipid Lowering: Beyond Statins (New Drugs 1)	Symposium 11 Lipid-lowering Therapy in Complex Clinical Settings: HIV, Cancer, and Chronic Kidney Disease	Symposium 12 KPS KSoLA Joint Symposium Bridging Cellular Physiology and Atherogenic Lipids	
10:00-10:10	Break				
10:10-10:20	Opening Address				
10:20-11:00	Plenary Lecture 1 Lipoprotein(a): the next frontier in cardiovascular prevention				
11:00-11:40	Special Lecture 1 (K) TBD				
11:45-12:45	Luncheon Symposium 1 (K)	Luncheon Symposium 2	Luncheon Symposium 3	Luncheon Symposium 4 (K)	Luncheon Symposium 5
12:45-13:45	Poster Presentation Session 1 (Studio 5, 6, 7, 6F)				
	Symposium 13 (K) *Session Time: 12:45-13:40 2026 KSoLA Awards for Scientific Excellence & Digital Health Media and Ethics	Symposium 14 Sex-specific Lipid Biology and Cardiometabolic Risk across the Lifespan			
13:45-15:15	Symposium 15 Official Launch of the 2026 KSoLA Guidelines for the Management of Dyslipidemia	VAS-KSoLA Joint Symposium Residual Cardiovascular Risk Beyond LDL-C: The Emerging Role of Lipoprotein(a) in Asia	Symposium 16 Evolution of High-risk Coronary Plaques: From Hemodynamics to Multimodality Assessment	Symposium 17 Metabolic Dysfunction, Fatty Liver, and Atherosclerosis	
15:20-16:00	Plenary Lecture 2 Closing the gap between guidelines and reality in dyslipidemia management				
16:00-16:10	Break				
16:10-17:40	Symposium 18 Intensive LDL-C Lowering in Primary Prevention	Symposium 19 Next-generation Lipid-lowering Therapies: CETP, APOC3, and ANGPTL3 Inhibition (New Drugs 2)	Symposium 20 Residual Cardiovascular Risk: Beyond LDL to Inflammation and Novel Targets	Symposium 21 KSSO-KSoLA Joint Symposium Atherogenic Obesity: Beyond BMI to Lipid Dysfunction	
[Day 3] September 12(Sat), 2026					
07:50-08:50	Breakfast Symposium 5	Breakfast Symposium 6	Breakfast Symposium 7	Breakfast Symposium 8	
08:50-10:20	Oral Presentation 3	TSLA-KSoLA Joint Symposium Contemporary Management of Residual Cardiovascular Risk in Asia	Symposium 22 Lipid beyond the Known: From Metabolic Pathways to Clinical Translation	MSA-KSoLA Joint Symposium From Diversity to Action: Ethnicity, Genetics, and Closing the Treatment Gap in Asian Dyslipidemia	
10:20-10:40	Coffee Break				
10:40-11:20	Plenary Lecture 3 Beyond LDL-C: lowering strategies for maximizing residual ASCVD risk reduction				
11:20-12:00	Plenary Lecture 4 Perspective on residual risk, inflammation, and atherosclerosis: from epidemiology to precision prevention				
12:00-13:00	Luncheon Symposium 6	Luncheon Symposium 7	Luncheon Symposium 8		
13:00-14:00	Poster Presentation Session 2 (Studio 5, 6, 7, 6F)				
	Symposium 23 KSM-KSoLA Joint Symposium Hypertension, Lipids, and Vascular Aging: Integrated Cardiovascular Risk Management	Symposium 24 KSCV-KSoLA Joint Symposium Beyond Stenting: Contemporary Management of Residual Coronary Risk	Symposium 25 KDA-KSoLA Joint Symposium Integrated Cardiometabolic Risk Management in Diabetes	Special Lecture 2 *Session Time: 13:20-13:50 Atherosclerosis and atherosclerotic cardiovascular disease in Asia: the knowledge gap for the determinants	
14:00-14:10	Break				
14:10-15:40	Symposium 26 Integrated Cardiovascular-kidney-metabolic Care: A Multidisciplinary Approach to CKM Syndrome	Symposium 24 AI-driven Innovations in Atherosclerosis	Symposium 28 Primary Prevention in Cardiovascular Disease: Beyond Traditional Risk Factors	Symposium 29 KES KSoLA Joint Symposium Lipid Metabolism Across Endocrine Disorders: From Mechanism to Clinical Practice	
16:20-17:50	Symposium 30 Neural and Genetic Control of Eating Behavior and Cardiometabolic Health	EAS-KSoLA Joint Symposium Bridging Europe and Korea in Dyslipidemia Management: Guidelines, Gaps, and Future Directions	Symposium 31 From Cells to Systems: Integrated Control of Cardiometabolic Health	Symposium 32 Environmental Cardiovascular Risk	
17:50-	Closing Ceremony (Room 1,2,3, 3F)				